Synonyms: DT-2216
Compound class:
Synthetic organic
Comment: DT2216 is a clinical stage PROTAC type protein degarder. It targets the BCL-XL protein (an anti-apoptotic protein that is overexpressed by some cancers) for degradation via the Von Hippel-Lindau (VHL) E3 ligase, and was developed for potential antitumour activity [2,4]. In vivo (in mice), The target protein binding moiety is based on the BCL-XL protein antagonist navitoclax (ABT-263) [2]. Since VHL is poorly expressed in platelets, DT2216 is significantly less toxic to platelets than parental navitoclax.
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
Ligand families/groups | PROTACs, molecular glues and other degraders |
Synonyms ![]() |
DT-2216 |
Database Links ![]() |
|
GtoPdb PubChem SID | 458923757 |
PubChem CID | 139331475 |
Search Google for chemical match using the InChIKey | PXVFFBGSTYQHRO-REQIQPEASA-N |
Search Google for chemicals with the same backbone | PXVFFBGSTYQHRO |
UniChem Compound Search for chemical match using the InChIKey | PXVFFBGSTYQHRO-REQIQPEASA-N |
UniChem Connectivity Search for chemical match using the InChIKey | PXVFFBGSTYQHRO-REQIQPEASA-N |
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.
✖
DT2216 (links to external site)
Cat. No. HY-130604 |